News

In a surprising move, Novo Nordisk joined forces in April with Dudum’s telehealth company, Hims & Hers, in a bid to expand sales of Wegovy to the growing pool of online patients.
Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that was one of the earliest movers in the weight loss drug market. The shares have lost 21% year-to-date due to multiple headwinds.
Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore.
Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...
Nevertheless, Novo Nordisk’s Ozempic and Rybelsus for diabetes and Wegovy for obesity are performing well, fueled by increasing demand.
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy – Hagens Berman ...
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
Novo Nordisk A/S (NYSE: NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...